Rheumatoid Arthritis
The Rheumatoid Arthritis pipeline: 79 tracked drugs, 36 approved for this indication.
36 approved / phase 47 Phase 313 Phase 21 Phase 1/216 Phase 16 preclinical / unstaged
Compare the share prices of listed companies in Rheumatoid Arthritis →
Total attributable cost
$13.1B
$9,662/patient
Drug spend
$4.5B
$3,331/patient
All severities and treatment regimens (US estimate) · US
The Rheumatoid Arthritis pipeline
Key trial results for every approved and late-stage drug: Rheumatoid Arthritis results by drug.